GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Switch, Change, Rearrange: Diabetes Medication Transitions, De-presc…

Jennifer Rosselli

S. Twillmann

State-of-the-Art, Treatment of Diabetic Kidney Disease (DKD)

Primary Care Education Consortium

S. Brunton

FLOW Trial Results: GLPs, the Kidneys, and Even More to Come!!

Robert Busch

Important Safety Information - Off-Target Effects of New Therapies f…

Ronald Goldenberg

Current Status of Prevention and Treatment of Diabetic Nephropathy

George Bakris

Patients in Cardiometabolic Jeopardy: Evolving Strategies for Cardio…

MUSC Cardiology

D. Lloyd-Jones

Use of Finerenone in Patients with Diabetes Who Have Kidney Disease

The Texas Heart Institute

G. Bakris

What's the Ideal Therapy for Obesity?

Stanford Medicine

A. Yeoh

Management of Kidney Health in CKD and DKD: A Cased-Based Multiple-c…

Bijin Thajudeen

ACC 2024 Insights: Evolving Pharmacology for HFrEF vs. HFpFF - With …

ACC 2024 Insights

M. Costanzo

SGLT2 Inhibitors and Heart Failure in Type-2 Diabetes Mellitus

Javed Butler

Diabetes and Heart Failure: The New Frontier

Mount Sinai Advanced Innovations in Heart Failure Symposium 2019

E. Braunwald

Updates in Nephrology

University of Colorado Department of Medicine

A. Jovanovich

Diabetes Management in CKD: KDIGO 2022 Clinical Practice Update

Cleveland Clinic Endocrinology & Metabolism Institute

L. Caramori

Updates on ADA Standards of Care - 2022

Scripps Health

A. Tsimikas, L. Vincent

Diabesity: New Trends in Management

Jefferson Health

K. Furlong